The Effect of Neuroepo on Cognition in Parkinson’s Disease Patients Is Mediated by Electroencephalogram Source Activity
We report on the quantitative electroencephalogram (qEEG) and cognitive effects of Neuroepo in Parkinson’s disease (PD) from a double-blind safety trial (https://clinicaltrials.gov/, number NCT04110678). Neuroepo is a new erythropoietin (EPO) formulation with a low sialic acid content with satisfact...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-06-01
|
| Series: | Frontiers in Neuroscience |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fnins.2022.841428/full |
| _version_ | 1811329662859608064 |
|---|---|
| author | Maria L. Bringas Vega Maria L. Bringas Vega Ivonne Pedroso Ibáñez Fuleah A. Razzaq Min Zhang Lilia Morales Chacón Peng Ren Lidice Galan Garcia Peng Gan Trinidad Virues Alba Carlos Lopez Naranjo Marjan Jahanshahi Marjan Jahanshahi Jorge Bosch-Bayard Jorge Bosch-Bayard Pedro A. Valdes-Sosa Pedro A. Valdes-Sosa |
| author_facet | Maria L. Bringas Vega Maria L. Bringas Vega Ivonne Pedroso Ibáñez Fuleah A. Razzaq Min Zhang Lilia Morales Chacón Peng Ren Lidice Galan Garcia Peng Gan Trinidad Virues Alba Carlos Lopez Naranjo Marjan Jahanshahi Marjan Jahanshahi Jorge Bosch-Bayard Jorge Bosch-Bayard Pedro A. Valdes-Sosa Pedro A. Valdes-Sosa |
| author_sort | Maria L. Bringas Vega |
| collection | DOAJ |
| description | We report on the quantitative electroencephalogram (qEEG) and cognitive effects of Neuroepo in Parkinson’s disease (PD) from a double-blind safety trial (https://clinicaltrials.gov/, number NCT04110678). Neuroepo is a new erythropoietin (EPO) formulation with a low sialic acid content with satisfactory results in animal models and tolerance in healthy participants and PD patients. In this study, 26 PD patients were assigned randomly to Neuroepo (n = 15) or placebo (n = 11) groups to test the tolerance of the drug. Outcome variables were neuropsychological tests and resting-state source qEEG at baseline and 6 months after administering the drug. Probabilistic Canonical Correlation Analysis was used to extract latent variables for the cognitive and for qEEG variables that shared a common source of variance. We obtained canonical variates for Cognition and qEEG with a correlation of 0.97. Linear Mixed Model analysis showed significant positive dependence of the canonical variate cognition on the dose and the confounder educational level (p = 0.003 and p = 0.02, respectively). Additionally, in the mediation equation, we found a positive dependence of Cognition with qEEG for (p = < 0.0001) and with dose (p = 0.006). Despite the small sample, both tests were powered over 89%. A combined mediation model showed that 66% of the total effect of the cognitive improvement was mediated by qEEG (p = 0.0001), with the remaining direct effect between dose and Cognition (p = 0.002), due to other causes. These results suggest that Neuroepo has a positive influence on Cognition in PD patients and that a large portion of this effect is mediated by brain mechanisms reflected in qEEG. |
| first_indexed | 2024-04-13T15:47:46Z |
| format | Article |
| id | doaj.art-a0432a0a64c340188c033940fae9c970 |
| institution | Directory Open Access Journal |
| issn | 1662-453X |
| language | English |
| last_indexed | 2024-04-13T15:47:46Z |
| publishDate | 2022-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Neuroscience |
| spelling | doaj.art-a0432a0a64c340188c033940fae9c9702022-12-22T02:40:55ZengFrontiers Media S.A.Frontiers in Neuroscience1662-453X2022-06-011610.3389/fnins.2022.841428841428The Effect of Neuroepo on Cognition in Parkinson’s Disease Patients Is Mediated by Electroencephalogram Source ActivityMaria L. Bringas Vega0Maria L. Bringas Vega1Ivonne Pedroso Ibáñez2Fuleah A. Razzaq3Min Zhang4Lilia Morales Chacón5Peng Ren6Lidice Galan Garcia7Peng Gan8Trinidad Virues Alba9Carlos Lopez Naranjo10Marjan Jahanshahi11Marjan Jahanshahi12Jorge Bosch-Bayard13Jorge Bosch-Bayard14Pedro A. Valdes-Sosa15Pedro A. Valdes-Sosa16Ministry of Education (MOE) Key Lab for Neuroinformation, The Clinical Hospital of Chengdu Brain Science Institute, University of Electronic Science and Technology of China, Chengdu, ChinaInternational Center of Neurological Restoration (CIREN), La Habana, CubaInternational Center of Neurological Restoration (CIREN), La Habana, CubaMinistry of Education (MOE) Key Lab for Neuroinformation, The Clinical Hospital of Chengdu Brain Science Institute, University of Electronic Science and Technology of China, Chengdu, ChinaMinistry of Education (MOE) Key Lab for Neuroinformation, The Clinical Hospital of Chengdu Brain Science Institute, University of Electronic Science and Technology of China, Chengdu, ChinaInternational Center of Neurological Restoration (CIREN), La Habana, CubaMinistry of Education (MOE) Key Lab for Neuroinformation, The Clinical Hospital of Chengdu Brain Science Institute, University of Electronic Science and Technology of China, Chengdu, ChinaCuban Neuroscience Center (CNEURO), La Habana, CubaMinistry of Education (MOE) Key Lab for Neuroinformation, The Clinical Hospital of Chengdu Brain Science Institute, University of Electronic Science and Technology of China, Chengdu, ChinaCuban Neuroscience Center (CNEURO), La Habana, CubaMinistry of Education (MOE) Key Lab for Neuroinformation, The Clinical Hospital of Chengdu Brain Science Institute, University of Electronic Science and Technology of China, Chengdu, ChinaMinistry of Education (MOE) Key Lab for Neuroinformation, The Clinical Hospital of Chengdu Brain Science Institute, University of Electronic Science and Technology of China, Chengdu, ChinaUCL Queen Square Institute of Neurology, London, United KingdomMinistry of Education (MOE) Key Lab for Neuroinformation, The Clinical Hospital of Chengdu Brain Science Institute, University of Electronic Science and Technology of China, Chengdu, ChinaMcGill Centre for Integrative Neuroscience, Montreal Neurological Institute, Montreal, QC, CanadaMinistry of Education (MOE) Key Lab for Neuroinformation, The Clinical Hospital of Chengdu Brain Science Institute, University of Electronic Science and Technology of China, Chengdu, ChinaMcGill Centre for Integrative Neuroscience, Montreal Neurological Institute, Montreal, QC, CanadaWe report on the quantitative electroencephalogram (qEEG) and cognitive effects of Neuroepo in Parkinson’s disease (PD) from a double-blind safety trial (https://clinicaltrials.gov/, number NCT04110678). Neuroepo is a new erythropoietin (EPO) formulation with a low sialic acid content with satisfactory results in animal models and tolerance in healthy participants and PD patients. In this study, 26 PD patients were assigned randomly to Neuroepo (n = 15) or placebo (n = 11) groups to test the tolerance of the drug. Outcome variables were neuropsychological tests and resting-state source qEEG at baseline and 6 months after administering the drug. Probabilistic Canonical Correlation Analysis was used to extract latent variables for the cognitive and for qEEG variables that shared a common source of variance. We obtained canonical variates for Cognition and qEEG with a correlation of 0.97. Linear Mixed Model analysis showed significant positive dependence of the canonical variate cognition on the dose and the confounder educational level (p = 0.003 and p = 0.02, respectively). Additionally, in the mediation equation, we found a positive dependence of Cognition with qEEG for (p = < 0.0001) and with dose (p = 0.006). Despite the small sample, both tests were powered over 89%. A combined mediation model showed that 66% of the total effect of the cognitive improvement was mediated by qEEG (p = 0.0001), with the remaining direct effect between dose and Cognition (p = 0.002), due to other causes. These results suggest that Neuroepo has a positive influence on Cognition in PD patients and that a large portion of this effect is mediated by brain mechanisms reflected in qEEG.https://www.frontiersin.org/articles/10.3389/fnins.2022.841428/fullNeuroepoEEGParkinson’s diseasesource analysisCanonical Correlation Analysis (CCA)whitening |
| spellingShingle | Maria L. Bringas Vega Maria L. Bringas Vega Ivonne Pedroso Ibáñez Fuleah A. Razzaq Min Zhang Lilia Morales Chacón Peng Ren Lidice Galan Garcia Peng Gan Trinidad Virues Alba Carlos Lopez Naranjo Marjan Jahanshahi Marjan Jahanshahi Jorge Bosch-Bayard Jorge Bosch-Bayard Pedro A. Valdes-Sosa Pedro A. Valdes-Sosa The Effect of Neuroepo on Cognition in Parkinson’s Disease Patients Is Mediated by Electroencephalogram Source Activity Frontiers in Neuroscience Neuroepo EEG Parkinson’s disease source analysis Canonical Correlation Analysis (CCA) whitening |
| title | The Effect of Neuroepo on Cognition in Parkinson’s Disease Patients Is Mediated by Electroencephalogram Source Activity |
| title_full | The Effect of Neuroepo on Cognition in Parkinson’s Disease Patients Is Mediated by Electroencephalogram Source Activity |
| title_fullStr | The Effect of Neuroepo on Cognition in Parkinson’s Disease Patients Is Mediated by Electroencephalogram Source Activity |
| title_full_unstemmed | The Effect of Neuroepo on Cognition in Parkinson’s Disease Patients Is Mediated by Electroencephalogram Source Activity |
| title_short | The Effect of Neuroepo on Cognition in Parkinson’s Disease Patients Is Mediated by Electroencephalogram Source Activity |
| title_sort | effect of neuroepo on cognition in parkinson s disease patients is mediated by electroencephalogram source activity |
| topic | Neuroepo EEG Parkinson’s disease source analysis Canonical Correlation Analysis (CCA) whitening |
| url | https://www.frontiersin.org/articles/10.3389/fnins.2022.841428/full |
| work_keys_str_mv | AT marialbringasvega theeffectofneuroepooncognitioninparkinsonsdiseasepatientsismediatedbyelectroencephalogramsourceactivity AT marialbringasvega theeffectofneuroepooncognitioninparkinsonsdiseasepatientsismediatedbyelectroencephalogramsourceactivity AT ivonnepedrosoibanez theeffectofneuroepooncognitioninparkinsonsdiseasepatientsismediatedbyelectroencephalogramsourceactivity AT fuleaharazzaq theeffectofneuroepooncognitioninparkinsonsdiseasepatientsismediatedbyelectroencephalogramsourceactivity AT minzhang theeffectofneuroepooncognitioninparkinsonsdiseasepatientsismediatedbyelectroencephalogramsourceactivity AT liliamoraleschacon theeffectofneuroepooncognitioninparkinsonsdiseasepatientsismediatedbyelectroencephalogramsourceactivity AT pengren theeffectofneuroepooncognitioninparkinsonsdiseasepatientsismediatedbyelectroencephalogramsourceactivity AT lidicegalangarcia theeffectofneuroepooncognitioninparkinsonsdiseasepatientsismediatedbyelectroencephalogramsourceactivity AT penggan theeffectofneuroepooncognitioninparkinsonsdiseasepatientsismediatedbyelectroencephalogramsourceactivity AT trinidadviruesalba theeffectofneuroepooncognitioninparkinsonsdiseasepatientsismediatedbyelectroencephalogramsourceactivity AT carloslopeznaranjo theeffectofneuroepooncognitioninparkinsonsdiseasepatientsismediatedbyelectroencephalogramsourceactivity AT marjanjahanshahi theeffectofneuroepooncognitioninparkinsonsdiseasepatientsismediatedbyelectroencephalogramsourceactivity AT marjanjahanshahi theeffectofneuroepooncognitioninparkinsonsdiseasepatientsismediatedbyelectroencephalogramsourceactivity AT jorgeboschbayard theeffectofneuroepooncognitioninparkinsonsdiseasepatientsismediatedbyelectroencephalogramsourceactivity AT jorgeboschbayard theeffectofneuroepooncognitioninparkinsonsdiseasepatientsismediatedbyelectroencephalogramsourceactivity AT pedroavaldessosa theeffectofneuroepooncognitioninparkinsonsdiseasepatientsismediatedbyelectroencephalogramsourceactivity AT pedroavaldessosa theeffectofneuroepooncognitioninparkinsonsdiseasepatientsismediatedbyelectroencephalogramsourceactivity AT marialbringasvega effectofneuroepooncognitioninparkinsonsdiseasepatientsismediatedbyelectroencephalogramsourceactivity AT marialbringasvega effectofneuroepooncognitioninparkinsonsdiseasepatientsismediatedbyelectroencephalogramsourceactivity AT ivonnepedrosoibanez effectofneuroepooncognitioninparkinsonsdiseasepatientsismediatedbyelectroencephalogramsourceactivity AT fuleaharazzaq effectofneuroepooncognitioninparkinsonsdiseasepatientsismediatedbyelectroencephalogramsourceactivity AT minzhang effectofneuroepooncognitioninparkinsonsdiseasepatientsismediatedbyelectroencephalogramsourceactivity AT liliamoraleschacon effectofneuroepooncognitioninparkinsonsdiseasepatientsismediatedbyelectroencephalogramsourceactivity AT pengren effectofneuroepooncognitioninparkinsonsdiseasepatientsismediatedbyelectroencephalogramsourceactivity AT lidicegalangarcia effectofneuroepooncognitioninparkinsonsdiseasepatientsismediatedbyelectroencephalogramsourceactivity AT penggan effectofneuroepooncognitioninparkinsonsdiseasepatientsismediatedbyelectroencephalogramsourceactivity AT trinidadviruesalba effectofneuroepooncognitioninparkinsonsdiseasepatientsismediatedbyelectroencephalogramsourceactivity AT carloslopeznaranjo effectofneuroepooncognitioninparkinsonsdiseasepatientsismediatedbyelectroencephalogramsourceactivity AT marjanjahanshahi effectofneuroepooncognitioninparkinsonsdiseasepatientsismediatedbyelectroencephalogramsourceactivity AT marjanjahanshahi effectofneuroepooncognitioninparkinsonsdiseasepatientsismediatedbyelectroencephalogramsourceactivity AT jorgeboschbayard effectofneuroepooncognitioninparkinsonsdiseasepatientsismediatedbyelectroencephalogramsourceactivity AT jorgeboschbayard effectofneuroepooncognitioninparkinsonsdiseasepatientsismediatedbyelectroencephalogramsourceactivity AT pedroavaldessosa effectofneuroepooncognitioninparkinsonsdiseasepatientsismediatedbyelectroencephalogramsourceactivity AT pedroavaldessosa effectofneuroepooncognitioninparkinsonsdiseasepatientsismediatedbyelectroencephalogramsourceactivity |